2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1027

Odanacatib Efficacy and Safety in Postmenopausal Women with Osteoporosis: 5-Year Data from the Extension of the Phase 3 Long-Term Odanacatib Fracture Trial
Abstract Number: 1887

Olfactory Impairment Is Associate with Cognitive Dysfunction and Regional Brain Atrophy in Systemic Sclerosis
Abstract Number: 1598

Olokizumab Treatment of Both Western and Asian Patients with Rheumatoid Arthritis Who Have Failed Anti-TNF Treatment Results in Sustained Improvements in Patient-Reported Outcomes
Abstract Number: 1506

One Third of Patients with Established Rheumatoid Arthritis (RA) Are Correctly Vaccinated Against Influenza and Pneumococcus and This Is Increasing: 3 Year Longitudinal Assessment of 776 Patients
Abstract Number: 113

Online Consultation for Chinese Patients with Rheumatic Diseases Based on Smart System of Disease Management (SSDM) Mobile Tools: A Study of Medical Economics
Abstract Number: 1182

Opiod Use and Death in Chronic Pain Patients with Systemic Lupus Erythematosis
Abstract Number: 369

Opioid Prescriptions and Adverse Reactions in Children and Adolescents without Serious Diseases
Abstract Number: 1850

Optimization of a Murine Model to Recapitulate Dermal and Pulmonary Features of SSc
Abstract Number: 2941

Optimization of Adalimumab on Refractory Uveitis of Behcet’s Syndrome. Multicenter Study of 23 Patients
Abstract Number: 2956

Optimization of Thiopurines with a Xanthine Oxidase Inhibitor in Patients with Autoimmune Systemic Diseases
Abstract Number: 1239

Optimizing Screening for Psoriatic Arthritis through a Shortened Psoriatic Arthritis Screening and Evaluation-2 (PASE-2) Tool
Abstract Number: 86

Optimizing the Efficiency of Patient Data Capture Using Smartphone Technology: Evaluation of the Correlation Between Promis Instruments for PRO Data Capture
Abstract Number: 412

Oral Glucocorticoids and Rates of Incident Diabetes Mellitus and Hypertension in Children with Juvenile Idiopathic Arthritis and Attention-Deficit/Hyperactivity Disorder
Abstract Number: 1988

Oral Health and Anti-Citrullinated Peptide Antibodies in Juvenile Idiopathic Arthritis
Abstract Number: 2320

Oropharyngeal Dysphagia in Autoimmune Myositis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].